{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T22:33:58Z","timestamp":1794090838817,"version":"4.8.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Bioanalytical Shared Resource\/Pharmacokinetics Core Facility"},{"name":"University Shared Resource Program at Oregon Health and Sciences University"},{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","award":["U54 AI 081680"],"award-info":[{"award-number":["U54 AI 081680"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Antiviral Drug Discovery and Development Center","award":["U19 AI 109680"],"award-info":[{"award-number":["U19 AI 109680"]}]},{"name":"60\u00b0 Pharmaceuticals, LLC"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.antiviral.2018.04.019","type":"journal-article","created":{"date-parts":[[2018,4,27]],"date-time":"2018-04-27T13:48:27Z","timestamp":1524836907000},"page":"12-19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Characterization and structure-activity relationship analysis of a class of antiviral compounds that directly bind dengue virus capsid protein and are incorporated into virions"],"prefix":"10.1016","volume":"155","author":[{"given":"Jessica L.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla","family":"Sheridan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Parkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2489-2467","authenticated-orcid":false,"given":"Lisa","family":"Frueh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana L.","family":"Jemison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleya","family":"Strode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Dow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Nilsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alec J.","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2018.04.019_bib1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.coviro.2016.09.003","article-title":"The quest for host targets to combat dengue virus infections","volume":"20","author":"Acosta","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.antiviral.2018.04.019_bib2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.virol.2008.08.021","article-title":"Temperature-dependent production of pseudo infectious dengue reporter virus particles by complementation","volume":"381","author":"Ansarah-Sobrinho","year":"2008","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2018.04.019_bib3","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2018.04.019_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1001220","article-title":"HIV capsid is a tractable target for small molecule therapeutic intervention","volume":"6","author":"Blair","year":"2010","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2018.04.019_bib5","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1590\/S0074-02762013000500010","article-title":"Chloroquine use improves dengue-related symptoms","volume":"108","author":"Borges","year":"2013","journal-title":"Memorias do Inst. Oswaldo Cruz"},{"key":"10.1016\/j.antiviral.2018.04.019_bib6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1128\/AAC.01429-12","article-title":"A novel inhibitor of dengue virus replication that targets the capsid protein","volume":"57","author":"Byrd","year":"2013","journal-title":"Antimicrob. agents Chemother."},{"key":"10.1016\/j.antiviral.2018.04.019_bib7","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(14)61060-6","article-title":"Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial","volume":"384","author":"Capeding","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2018.04.019_bib8","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1128\/AAC.04177-14","article-title":"The bioactive lipid 4-hydroxyphenyl retinamide inhibits flavivirus replication","volume":"59","author":"Carocci","year":"2015","journal-title":"Antimicrob. agents Chemother."},{"key":"10.1016\/j.antiviral.2018.04.019_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004058","article-title":"Proteasome inhibition suppresses dengue virus egress in antibody dependent infection","volume":"9","author":"Choy","year":"2015","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.antiviral.2018.04.019_bib10","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1128\/JVI.74.1.564-572.2000","article-title":"Alpha-glucosidase inhibitors reduce dengue virus production by affecting the initial steps of virion morphogenesis in the endoplasmic reticulum","volume":"74","author":"Courageot","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.04.019_bib11","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1128\/AAC.46.9.3057-3060.2002","article-title":"Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro","volume":"46","author":"Delaney","year":"2002","journal-title":"Antimicrob. agents Chemother."},{"key":"10.1016\/j.antiviral.2018.04.019_bib12","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1126\/science.1077215","article-title":"Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids","volume":"299","author":"Deres","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2018.04.019_bib13","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.bmcl.2010.10.131","article-title":"Discovery of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of inhibitors of HIV-1 capsid assembly","volume":"21","author":"Fader","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.antiviral.2018.04.019_bib14","doi-asserted-by":"crossref","first-page":"9411","DOI":"10.1128\/JVI.00101-13","article-title":"Flaviviruses are sensitive to inhibition of thymidine synthesis pathways","volume":"87","author":"Fischer","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.04.019_bib15","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1093\/infdis\/jiu319","article-title":"A nuclear transport inhibitor that modulates the unfolded protein response and provides in vivo protection against lethal dengue virus infection","volume":"210","author":"Fraser","year":"2014","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.04.019_bib16","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1743-422X-6-10","article-title":"Development of real time PCR for detection and quantitation of Dengue Viruses","volume":"6","author":"Gurukumar","year":"2009","journal-title":"Virol. J."},{"key":"10.1016\/j.antiviral.2018.04.019_bib17","doi-asserted-by":"crossref","first-page":"745","DOI":"10.4269\/ajtmh.2012.11-0784","article-title":"Economic cost of dengue in Puerto Rico","volume":"86","author":"Halasa","year":"2012","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.antiviral.2018.04.019_bib18","doi-asserted-by":"crossref","first-page":"830","DOI":"10.4269\/ajtmh.1982.31.830","article-title":"Dengue virus-specific and flavivirus group determinants identified with monoclonal antibodies by indirect immunofluorescence","volume":"31","author":"Henchal","year":"1982","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.antiviral.2018.04.019_bib19","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.virol.2009.10.027","article-title":"The dengue virus type 2 envelope protein fusion peptide is essential for membrane fusion","volume":"396","author":"Huang","year":"2010","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2018.04.019_bib20","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1128\/AAC.42.12.3179","article-title":"Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide derivative, alone and in combination with (-)beta-L-2',3'-dideoxy-3'-thiacytidine","volume":"42","author":"King","year":"1998","journal-title":"Antimicrob. agents Chemother."},{"key":"10.1016\/j.antiviral.2018.04.019_bib21","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.antiviral.2013.09.013","article-title":"Ten years of dengue drug discovery: progress and prospects","volume":"100","author":"Lim","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.04.019_bib22","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.tips.2013.11.006","article-title":"Current progress in antiviral strategies","volume":"35","author":"Lou","year":"2014","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.antiviral.2018.04.019_bib23","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/S1473-3099(14)70730-3","article-title":"Efficacy and safety of celgosivir in patients with dengue fever (CELADEN): a phase 1b, randomised, double-blind, placebo-controlled, proof-of-concept trial","volume":"14","author":"Low","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.04.019_bib24","doi-asserted-by":"crossref","first-page":"3414","DOI":"10.1073\/pnas.0305892101","article-title":"Solution structure of dengue virus capsid protein reveals another fold","volume":"101","author":"Ma","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2018.04.019_bib25","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01960-15","article-title":"Suppression of drug resistance in dengue virus","volume":"6","author":"Mateo","year":"2015","journal-title":"mBio"},{"key":"10.1016\/j.antiviral.2018.04.019_bib26","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/978-1-4939-0348-1_6","article-title":"Pseudo-infectious reporter virus particles for measuring antibody-mediated neutralization and enhancement of dengue virus infection","volume":"1138","author":"Mukherjee","year":"2014","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.antiviral.2018.04.019_bib27","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.virusres.2012.01.009","article-title":"A small-molecule inhibitor of deubiquitinating enzyme USP14 inhibits Dengue virus replication","volume":"165","author":"Nag","year":"2012","journal-title":"Virus Res."},{"key":"10.1016\/j.antiviral.2018.04.019_bib28","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.antiviral.2011.10.002","article-title":"Celgosivir treatment misfolds dengue virus NS1 protein, induces cellular pro-survival genes and protects against lethal challenge mouse model","volume":"92","author":"Rathore","year":"2011","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.04.019_bib29","doi-asserted-by":"crossref","first-page":"11540","DOI":"10.1128\/JVI.01745-14","article-title":"Characterization of the mode of action of a potent dengue virus capsid inhibitor","volume":"88","author":"Scaturro","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.04.019_bib30","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1089\/adt.2010.0321","article-title":"High-content assay to identify inhibitors of dengue virus infection","volume":"8","author":"Shum","year":"2010","journal-title":"Assay drug Dev. Technol."},{"key":"10.1016\/j.antiviral.2018.04.019_bib31","doi-asserted-by":"crossref","first-page":"5533","DOI":"10.1128\/JVI.00365-14","article-title":"Inhibition of dengue virus replication by a class of small-molecule compounds that antagonize dopamine receptor d4 and downstream mitogen-activated protein kinase signaling","volume":"88","author":"Smith","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.04.019_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004851","article-title":"Extended evaluation of virological, immunological and pharmacokinetic endpoints of CELADEN: a randomized, placebo-controlled trial of celgosivir in dengue fever patients","volume":"10","author":"Sung","year":"2016","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.antiviral.2018.04.019_bib33","doi-asserted-by":"crossref","first-page":"7512","DOI":"10.1016\/j.bmcl.2012.10.034","article-title":"Inhibition of HIV-1 capsid assembly: optimization of the antiviral potency by site selective modifications at N1, C2 and C16 of a 5-(5-furan-2-yl-pyrazol-1-yl)-1H-benzimidazole scaffold","volume":"22","author":"Tremblay","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.antiviral.2018.04.019_bib34","doi-asserted-by":"crossref","first-page":"e785","DOI":"10.1371\/journal.pntd.0000785","article-title":"A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults","volume":"4","author":"Tricou","year":"2010","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.antiviral.2018.04.019_bib35","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1411037","article-title":"Efficacy of a tetravalent dengue vaccine in children in Latin America","volume":"372","author":"Villar","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.04.019_bib36","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.antiviral.2015.12.008","article-title":"Optimizing celgosivir therapy in mouse models of dengue virus infection of serotypes 1 and 2: the search for a window for potential therapeutic efficacy","volume":"127","author":"Watanabe","year":"2016","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.04.019_bib37","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.antiviral.2012.07.008","article-title":"Dose- and schedule-dependent protective efficacy of celgosivir in a lethal mouse model for dengue virus infection informs dosing regimen for a proof of concept clinical trial","volume":"96","author":"Watanabe","year":"2012","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.04.019_bib38","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1093\/cid\/civ949","article-title":"Lovastatin for the treatment of adult patients with dengue: a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Whitehorn","year":"2016","journal-title":"Clin. Infect. Dis. Offi. Publ. Infect. Dis. Soc. Am."},{"key":"10.1016\/j.antiviral.2018.04.019_bib39","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/1745-6215-13-203","article-title":"Lovastatin for adult patients with dengue: protocol for a randomised controlled trial","volume":"13","author":"Whitehorn","year":"2012","journal-title":"Trials"},{"key":"10.1016\/j.antiviral.2018.04.019_bib40","doi-asserted-by":"crossref","first-page":"714","DOI":"10.3201\/eid0704.017420","article-title":"West Nile virus infection in the golden hamster (Mesocricetus auratus): a model for West Nile encephalitis","volume":"7","author":"Xiao","year":"2001","journal-title":"Emerg. Infect. Dis."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016635421730339X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016635421730339X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:27:21Z","timestamp":1759062441000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016635421730339X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":40,"alternative-id":["S016635421730339X"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.04.019","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization and structure-activity relationship analysis of a class of antiviral compounds that directly bind dengue virus capsid protein and are incorporated into virions","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.04.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}